GONORRHOEA. Use of lidocaine as a diluent when using ceftriaxone (see Appendix 1)

Transcription

1 Key practice notes: 1 st line therapy GONORRHOEA Decreasing sensitivity of gonorrhoea to cephalosporins is now a real threat: CEFTRIAXONE 500mg IM stat first-line for all gonococcal infections AZITHROMYCIN 1g co-treatment (regardless of Chlamydia result) for all cases TEST OF CURE for all patients regardless of anatomical site of infection Use of lidocaine as a diluent when using ceftriaxone (see Appendix 1) Diagnosis 1. Microscopy Very useful for acutely symptomatic patients with urethral discharge, proctitis or cervicitis. Gram negative intracellular diplococci (GNDC) (NB Microscopy provides a provisional diagnosis always make this clear. Final diagnosis is the result of the PCR and/or culture) Where on-site microscopy unavailable dry the slide on a hotplate for transport to your slide-reading lab as per protocol for gram-stain and microscopy 2. NAAT NAAT testing is our primary method of excluding gonorrhoea from all anatomical sites. We use the Abbott RealTime Gonorrhoea/ Chlamydia trachomatis PCR test across the whole of NHSGGC. Borderline positive GC NAAT results are confirmed in a second test in Edinburgh before the result is released. All positive tests are sent to the Edinburgh reference lab for sequencing, and any discrepant tests notified (subject to regular audit) The aim is to reduce unnecessary invasive swabs and examinations. Culture should still be offered to selected cases only. A positive result from a GC NAAT should always, with patient consent, have culture sensitivity testing attempted by repeat sampling and sending the specimen to the appropriate bacteriology lab where direct plating or rapid swab transport is available. This will enable us to continue to monitor antibiotic sensitivities. Repeat NAAT should only be undertaken if the diagnosis does not fit the clinical picture at all. There is a small risk of false positives with NAAT testing so information / partner notification should take this into account, especially if the clinical likelihood is low. See the table below on how to manage results from both tests. Urine samples should not be taken from women as there is a lower sensitivity compared to vulvovaginal swabs. Page 1 of 8

2 3. Culture Culture should be taken only in the following cases: Any NAAT-positive case agreeing to attempted culture isolation Contacts of gonorrhoea Any genital or rectal discharge Suspected PID / cervicitis Carefully plate each sample onto non-selective (CBA) and selective (GC sel and LCAT) plates. Cover one quarter of Petri dish. If you do not have local plating then transfer a charcoal swabs to your local lab as soon as possible. Ensure that the tests on NaSH match precisely what you have ordered from the lab. Do not confuse GC NAAT with GC culture. Site of tests for NAAT testing: Male Urine Female Vulvovaginal swab *Rectum *Pharynx * Only in MSM who report receptive anal or oral sex. Proctoscopy if symptoms, otherwise blind swabs Pharynx (if high index of suspicion, e.g.: GC contact or Sexual assault) NB urine is not ideal sample for GC exclusion in women Site of swabs for culture (selected patients) Male Urethra *rectum (+NAAT) **pharynx Female Endocervical **Urethra (only if urethral discharge) **rectum (+ NAAT) **pharynx *msm-receptive anal sex **High index of suspicion, e.g.gc contact or Sexual assault Examples of typical test sets: A routine asymptomatic screen consists of: Male (non-msm) Urine for GC/Ct NAAT No exam needed MSM Urine for GC/Ct NAAT *Rectal swab for GC/Ct NAAT Page 2 of 8

3 *Pharyngeal swab for GC/Ct NAAT *if indicated by sexual history No exam needed. Separate forms required for samples from different sites Woman Vulvovag swab for GC/Ct NAAT No exam needed. Plus opt-out bloods for STS/HIV/HepBcAb A symptomatic screen consists of: Urethral discharge Urethral Gram stain and culture Urine for GC/Ct NAAT MSM with rectal discharge / proctitis Urine for GC/Ct NAAT Rectal swab for GC/Ct NAAT Rectal Gram stain and culture for GC (by proctoscopy) (plus HSV/syphilis PCR etc) Woman with cervicitis proctitis Vulvovaginal swab for GC/Ct NAAT Endocervical Gram stain and culture Rectal Gram stain (if proctitis by proctoscopy) and culture Rectal Chlamydia/GC NAAT Plus opt-out bloods for STS/HIV/HepBcAb Treatment Gonoccocal antibiotic resistance Current resistance (Jul 2012) of GC isolates in Glasgow was 27% for Ciprofloxacin. Azithromycin alone is inadequate treatment for gonorrhoea as high-level resistance has been seen locally. Doxycycline is also ineffective. There is increasing drift of sensitivity to cephalosporins, mostly associated with certain prevalent sequence types. Usually we treat gonorrhoea before sensitivities are available blind and we should use a drug that will cure >95% of infections. Parenteral ceftriaxone is the preferred choice in light of emerging data and consensus from BASHH and Bacterial SIG. Cefixime is now considered second-line therapy especially for extra-genital sites of infection. Both are considered safe in single dose in pregnancy (WHO data). Co-treatment with azithromycin Emerging data suggest that co-treatment with azithromycin may protect cephalosporins from resistance. Our policy is to co-treat all patients in any case due to risk of Chlamydia regardless of the Chlamydia result. Current WHO advice of azithromycin 2g with ceftriaxone conflicts with UK and US advice of 1g azithromycin with ceftriaxone. Page 3 of 8

4 Do NOT use ciprofloxacin blind if you suspect penicillin allergy it won t work! Blind treatment (no sensitivities available) of suspected uncomplicated urethral or vaginal infection (where NAAT only see section 3 below): Ceftriaxone 500mg I/M (see appendix 1) with azithromycin 1G po stat Alternative if IM injection contra-indicated (eg bleeding disorder) or patient refuses injectable therapy but not normally recommended because of sub-optimal activity at the pharyngeal site: Cefixime 400mg po stat with azithromycin 1G po stat Alternative if history of allergy to cephalosporin (or other -lactam antibiotic) or immediate hypersensitivity reaction to penicillin: Azithromycin 2G stat orally or Spectinomycin 2g i/m (see appendix 2) with azithromycin 1G po stat does not cover oropharynx) NB spectinomycin supplies can be difficult to obtain, a named patient form must be used. If immediate microscopy not available. If subsequent microscopy at Sandyford confirms gonorrhoea the patient will need to be recalled for treatment as above. Purulent urethral discharge does not guarantee a diagnosis of gonorrhoea however the patient may leave the clinic with treatment for both gonorrhoea and chlamydia as below if the diagnosis of urethritis is clinically obvious. Co-treatment of chlamydia: National data from STISS 2005 shows co-infection with chlamydia in 40% of women, 31% of heterosexual men and 14% of MSM. We recommend co-treatment for all with azithromycin rather than doxycycline, (except where rectal chlamydia is detected where a long doxycycline course is used). Page 4 of 8

5 Gonorrhoea identified on culture and/or NAAT: Try and establish antibiotic susceptibility if patient referred in for management of positive culture elsewhere (i.e. phone respective laboratory). Below is a suggested approach to managing positive results. If in doubt speak to a senior GUM colleague. Culture positive (GC NAAT positive OR negative OR GC NAAT not done) Treat for gonorrhoea with ceftriaxone or ciprofloxacin as per sensitivities provided by laboratory Partner notification as per protocol GC NAAT Positive (GC Cultures not done or GC culture negative) Take swab/s from same site as GC NAAT positive sample from and send for GC culture (if not already antibiotic treated) Highlight on form that GC NAAT positive. SEND TO BACTERIOLOGY Treat for gonorrhoea as above, excluding ciprofloxacin Partner notification as per protocol If a GP/ hospital clinician contacts you about a NAAT positive GC result in the community try to encourage them to send the patient to the Sandyford for cultures/ treatment and partner notification to occur. Pass the details to the Shared Care Helpline ( ) for follow up. Urethral / Vulvovaginal /pharyngeal/rectal Ciprofloxacin 500mg oral stat if known sensitive on culture with azithromycin 1G po stat (not if risk of pregnancy) or Ceftriaxone 500mg IM stat (see appendix 1) with azithromycin 1G po stat (If risk of pregnancy or sensitivity unavailable) Page 5 of 8

6 Complicated Gonococcal infection: (esp disseminated gonococcal infection (DGI) but also PID and epididymo-orchitis (EO)). Discuss with senior staff first. Admission to the local hospital may need to be considered for parenteral antibiotics (see below for treatment suggestion or contact your local microbiologist for advice): DGI: Cefotaxime 1g IV 8 hrly until clinical improvement followed by cefixime 400mg po bd to complete a 14 day course PLUS Doxycycline 100 mg bd for 7 days. PID: Ceftriaxone 500mg I/M stat PLUS IV/Oral antibiotic treatment to cover chlamydia as tolerated (doxycycline 100mg bd + metronidazole 400 mg bd) to complete 14 days EO: Ceftriaxone 500mg IM single dose, PLUS Doxycycline 100mg po bd 14 days Partner Notification As a minimum give IM ceftriaxone 500mg stat with azithromycin All patients diagnosed with gonorrhoea should see a sexual health adviser at diagnosis and at each follow up visit, until partner notification is documented as complete. Partners should be screened for infection and advised to avoid sex until their infection status is confirmed on culture/ NAAT, and (if applicable) their partner has tested negative. Rectal gonorrhoea is a marker for unsafe sex and may indicate further risk reduction work is needed Around 50% of contacts who report exposure to gonorrhoea are found to have gonorrhoea themselves. Epidemiological treatment has the advantage of immediate reassurance and prevents onward transmission and additional morbidity should they be infected. Patients who later default will have been securely treated. However, as gonorrhoea may be missed on a first screen the chance to extend partner notification may be lost. Half of these patients will take antibiotics unnecessarily. The decision to treat epidemiologically must be carefully discussed with the patient and these advantages and disadvantages outlined. Patients not treated should re-attend for a repeat GC test within the next two weeks. If treatment is given check to see if sensitivities from source are available, if not follow guidance for blind treatment (1 above). If exposure is likely at the pharynx or rectum then ceftriaxone is preferred. Page 6 of 8

7 Follow-up Test of cure is recommended after 3 weeks by national guidelines in all cases. Test of cure should be taken in: ALL CASES. (of particular importance in the following cases): if pharyngeal gonorrhoea (NAAT at 3 weeks) if the patient is pregnant (NAAT at 3 weeks) if symptoms have not cleared within 48h especially if urethral discharge persists, in which case repeat culture is needed to recheck antibiotic susceptibility where antibiotic susceptibility is in doubt following receipt of reference lab results following treatment with spectinomycin or azithromycin alone due to allergy. Review antibiotic sensitivities if available. Check carefully the date of specimen collection on all reports several laboratory reports may be sent on a single isolate. Be careful on NASH as sensitivities may relate to more than one organism if multiple pathogens identified. Offer final review at 3 months for repeat STS ± HIV test. Sequence types are now imported into NaSH about a month behind: they can be useful e.g. in multiple anatomic sites (same or different infection?) and resolving issues about which partners are linked (should be same ST). Patients can have more than one strain of GC at the same time. Referral to the Sexual Health Adviser or nurse with SHA competencies to check adherence to management of treatment and to complete partner notification and to determine whether further follow up via phone is necessary. References: Bignell & Fitzgerald. (2011). UK National Guideline for the Management of Gonorrhoea in Adults. International Journal of STD & AIDS 22: British Association for Sexual Health and HIV Clinical Effectiveness Group. (2012). United Kingdom National Guideline for Gonorrhoea Testing. World Health Organisation. (2012). European Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults. Spectinomycin manufacturer s instructions: Page 7 of 8

8 APPENDIX 1 Preparation and Administration of Ceftriaxone 500mg deep intramuscular Injection To reduce the pain experienced by patients receiving intramuscular ceftriaxone the drug is administered with 1% lidocaine (lignocaine) 1. Take two vials of ceftriaxone 250mg powder and a vial of lidocaine 1% injection containing at least 2ml 2. Draw up 2ml lidocaine 1% into a syringe. 3. Reconstitute each vial of 250mg ceftriaxone with 1ml of lidocaine 1%. 4. Draw up the reconstituted ceftriaxone solution from each vial into one syringe to make ceftriaxone 500mg in 2ml. 5. Administer the 2ml solution of ceftriaxone 500mg by deep intramuscular injection. NOTE: Lidocaine must be prescribed. APPENDIX 2 Preparation and Administration of Spectinomycin 2g Intramuscular Injection Alternative treatment if history of allergy to cephalosporin (or other -lactam antibiotic) or immediate hypersensitivity reaction to penicillin: Spectinomycin 2g reconstituted with 3.2ml bacteriostatic water (supplied) and to shake vigorously. Once dissolved to be drawn up as 5ml. The solution should be administered by deep intramuscular injection. Page 8 of 8